

L Number	Hits	Search Text	DB	Time stamp
1	5077	yano-k\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 15:58
2	10	yano-k\$.in. and hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 15:59
3	12	detmar-m\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:00
4	0	lachgar-s\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:00
5	6	bonafe-j\$.in.	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:00
6	867	VEGF and hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:01
7	34	VEGF SAME hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:04
8	207	angiogen\$ SAME hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:04
9	173	angiogenesis SAME hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:04
10	112	angiogenesis WITH hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:11
11	769	VEGF AND angiogen\$ AND hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:11
12	589	VEGF SAME angiogen\$ AND hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:11
13	11	VEGF SAME angiogen\$ SAME hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:12
14	0	Angiogen AND follicle	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:12
15	1215	Angiogen\$ AND follicle	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:12

16	519	Angiogen\$ AND Hair ADJ follicle	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:13
17	318	VEGF AND Angiogen\$ AND Hair ADJ follicle	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:13
18	309	VEGF SAME Angiogen\$ AND Hair ADJ follicle	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:13
19	3	VEGF SAME Angiogen\$ SAME Hair ADJ follicle	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:13
20	421	VEGF and keratinocyte and hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:14
21	69	VEGF SAME keratinocyte and hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:14
22	3	VEGF SAME keratinocyte SAME hair	USPAT; US-PGPUB; EPO; JPO; DERWENT	2003/06/29 16:14

FILE 'HOME' ENTERED AT 14:56:08 ON 29 JUN 2003

=> fil medline biosis caplus cancerlit embase
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'MEDLINE' ENTERED AT 14:56:32 ON 29 JUN 2003

FILE 'BIOSIS' ENTERED AT 14:56:32 ON 29 JUN 2003
COPYRIGHT (C) 2003 BIOLOGICAL ABSTRACTS INC.(R)

FILE 'CAPLUS' ENTERED AT 14:56:32 ON 29 JUN 2003
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER
AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CANCERLIT' ENTERED AT 14:56:32 ON 29 JUN 2003

FILE 'EMBASE' ENTERED AT 14:56:32 ON 29 JUN 2003
COPYRIGHT (C) 2003 Elsevier Science B.V. All rights reserved.

=> s yan-K?/au and (VEGF or keratinocyte or hair)
L1 21 YANO-K?/AU AND (VEGF OR KERATINOCYTE OR HAIR)
=> dup rem 11
PROCESSING COMPLETED FOR L1
L2 12 DUP REM L1 (9 DUPLICATES REMOVED)

=> d 1-12 ti so

L2 ANSWER 1 OF 12 CAPLUS COPYRIGHT 2003 ACS
TI Soft water-generating spray container having ion exchange resin, and water
hardness indicator paper
SO Jpn. Kokai Tokkyo Koho, 2 pp.
CODEN: JKXXAF

L2 ANSWER 2 OF 12 MEDLINE DUPLICATE 1
TI Thrombospondin-1 plays a critical role in the induction of hair
follicle involution and vascular regression during the catagen phase.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (2003 Jan) 120 (1)
14-9.
Journal code: 0426720. ISSN: 0022-202X.

L2 ANSWER 3 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL
ABSTRACTS INC.
TI Suppression of multistage skin carcinogenesis in mice deficient for
placental growth factor.
SO Journal of Investigative Dermatology, (July, 2002) Vol. 119, No. 1, pp.
224. http://www.jidonline.org. print.
Meeting Info.: 63rd Annual Meeting of the Society for Investigative
Dermatology Los Angeles, California, USA May 15-18, 2002
ISSN: 0022-202X.

L2 ANSWER 4 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL
ABSTRACTS INC.
TI The endogenous angiogenesis inhibitor thrombospondin-1 plays a critical
role in the induction of hair follicle involution and vascular
regression during catagen.
SO Journal of Investigative Dermatology, (July, 2002) Vol. 119, No. 1, pp.
208. http://www.jidonline.org. print.
Meeting Info.: 63rd Annual Meeting of the Society for Investigative
Dermatology Los Angeles, California, USA May 15-18, 2002
ISSN: 0022-202X.

L2 ANSWER 5 OF 12 MEDLINE DUPLICATE 2
TI Multiple pilomatrixoma without myotonic dystrophy.
SO BRITISH JOURNAL OF PLASTIC SURGERY, (2001 Apr) 54 (3) 278-9.
Journal code: 2984714R. ISSN: 0007-1226.

L2 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS
TI Methods of modulating hair growth
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2

L2 ANSWER 7 OF 12 MEDLINE DUPLICATE 3
TI Control of hair growth and follicle size by VEGF
-mediated angiogenesis.
SO JOURNAL OF CLINICAL INVESTIGATION, (2001 Feb) 107 (4) 409-17.
Journal code: 7802877. ISSN: 0021-9738.

L2 ANSWER 8 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL
ABSTRACTS INC.
TI Inverse regulation of the angiogenesis factor VEGF and the
angiogenesis inhibitor thrombospondin-1 and TSP-2 in human epidermal
keratinocytes.
SO Journal of Investigative Dermatology, (August, 2001) Vol. 117, No. 2, pp.
391. print.
Meeting Info.: 62nd Annual Meeting of the Society for Investigative
Dermatology Washington, DC, USA May 09-12, 2001
ISSN: 0022-202X.

L2 ANSWER 9 OF 12 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Skin closure using 2-octylcyanoacrylate in tympanoplasty.
SO Oto-Rhino-Laryngology Tokyo, (2001) 44/4 (30-33).
Refs: 9
ISSN: 0386-9687 CODEN: JITEBR

L2 ANSWER 10 OF 12 MEDLINE DUPLICATE 4
TI Thrombospondin-1 suppresses wound healing and granulation tissue
formation
in the skin of transgenic mice.
SO EMBO JOURNAL, (2000 Jul 3) 19 (13) 3272-82.
Journal code: 8208664. ISSN: 0261-4189.

L2 ANSWER 11 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL
ABSTRACTS INC.
TI Murine hair follicle growth is angiogenesis-dependent.
SO Journal of Investigative Dermatology, (April, 2000) Vol. 114, No. 4, pp.
755.
Meeting Info.: 61st Annual Meeting of the Society for Investigative
Dermatology. Chicago, Illinois, USA May 10-14, 2000
ISSN: 0022-202X.

L2 ANSWER 12 OF 12 BIOSIS COPYRIGHT 2003 BIOLOGICAL
ABSTRACTS INC.DUPLICATE 5
TI TREATMENT OF OSIMIDROSIS BY THE SKOOG METHOD.
SO JPN J PLAST RECONSTR SURG, (1988) 31 (10), 908-914.
CODEN: KEGEAC. ISSN: 0021-5228.

=> d 6

L2 ANSWER 6 OF 12 CAPLUS COPYRIGHT 2003 ACS
AN 2001:747567 CAPLUS
DN 135:277728
TI Methods of modulating hair growth
IN Detmar, Michael; Yano, Kiichiro
PA The General Hospital Corporation, USA
SO PCT Int. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2001074317 A1 20011011 WO 2001-US8889 20010321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT,
RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,
VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
EP 1267800 A1 20030102 EP 2001-920564 20010321
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
PRAI US 2000-193597P A2 20000331
WO 2001-US8889 W 20010321
RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS
RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s detmar-m?/au and (vegf or keratino? or hair)
L3 233 DETMAR-M?/AU AND (VEGF OR KERATINO? OR HAIR)

=> dup rem l3
PROCESSING COMPLETED FOR L3
L4 91 DUP REM L3 (142 DUPLICATES REMOVED)

=> d 60-690 ti so

L4 ANSWER 60 OF 91 MEDLINE DUPLICATE 29
TI Increased expression of vascular permeability factor (vascular endothelial
growth factor) in bullous pemphigoid, dermatitis herpetiformis, and
erythema multiforme.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1995 May) 104 (5)
744-9.
Journal code: 0426720. ISSN: 0022-202X.

L4 ANSWER 61 OF 91 BIOSIS COPYRIGHT 2003 BIOLOGICAL
ABSTRACTS INC.
TI Vascular permeability factor (vascular endothelial growth factor) is a
keratinocyte-derived potent mitogen for dermal endothelial cells:
Induction by TGF-alpha and hypoxia
SO Journal of Investigative Dermatology, (1995) Vol. 104, No. 4, pp. 590.
Meeting Info.: Annual Meeting of the Society for Investigative Dermatology
Chicago, Illinois, USA May 24-28, 1995

ISSN: 0022-202X.

L4 ANSWER 62 OF 91 MEDLINE DUPLICATE 30
TI Vascular permeability factor/vascular endothelial growth factor: an important mediator of angiogenesis in malignancy and inflammation.
SO INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY, (1995 May-Jun) 107 (1-3)
233-5. Ref: 18
Journal code: 9211652. ISSN: 1018-2438.

L4 ANSWER 63 OF 91 MEDLINE DUPLICATE 31
TI Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1995 Jul) 105 (1)
44-50.
Journal code: 0426720. ISSN: 0022-202X.

L4 ANSWER 64 OF 91 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI VPF/VEGF, microvascular hyperpermeability, and angiogenesis.
SO Journal of Leukocyte Biology, (1995) Vol. 0, No. SUPPL., pp. 18.
Meeting Info.: Thirty-first National Meeting of the Society for Leukocyte Biology on Host Defense Against Infections and Cancer Marco Island, Florida, USA September 13-16, 1995
ISSN: 0741-5400.

L4 ANSWER 65 OF 91 MEDLINE DUPLICATE 32
TI Overexpression of vascular permeability factor/vascular endothelial growth factor and its receptors in psoriasis.
SO JOURNAL OF EXPERIMENTAL MEDICINE, (1994 Sep 1) 180 (3) 1141-6.
Journal code: 2985109R. ISSN: 0022-1007.

L4 ANSWER 66 OF 91 CAPLUS COPYRIGHT 2003 ACS DUPLICATE 33
TI Effects of ecdysterone on the differentiation of normal human keratinocytes in vitro
SO European Journal of Dermatology (1994), 4(7), 558-62
CODEN: EJDEE4; ISSN: 1167-1122

L4 ANSWER 67 OF 91 MEDLINE DUPLICATE 34
TI Phospholipid analogue hexadecylphosphocholine inhibits proliferation and phosphatidylcholine biosynthesis of human epidermal keratinocytes in vitro.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1994 Apr) 102 (4)
490-4.
Journal code: 0426720. ISSN: 0022-202X.

L4 ANSWER 68 OF 91 MEDLINE DUPLICATE 35
TI Vellus hair follicle-derived keratinocyte culture: a new experimental model in human hair research.
SO SKIN PHARMACOLOGY, (1994) 7 (1-2) 27-32.
Journal code: 8810069. ISSN: 1011-0283.

L4 ANSWER 69 OF 91 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI Alterations of lymphocyte subsets in patients with Adamantades-Bechet's disease and enhanced lymphocyte interaction with human dermal microvascular endothelial cells and human keratinocytes in vitro.
SO Wechsler, B. [Editor], Godeau, P. [Editor]. International Congress Series, (1993) No. 1037, pp. 40-44. International Congress Series; Bechet's disease.
Publisher: Elsevier Science Publishers B.V. PO Box 211, Sara Burgerhartstraat 25, 1000 AE Amsterdam, Netherlands.
Meeting Info.: 6th International Conference Paris, France June 30-July 1, 1993
ISSN: 0531-5131. ISBN: 0-444-81615-1.

L4 ANSWER 70 OF 91 MEDLINE DUPLICATE 36
TI Culture of hair matrix and follicular keratinocytes.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1993 Jul) 101 (1 Suppl) 130S-134S.
Ref: 56
Journal code: 0426720. ISSN: 0022-202X.

L4 ANSWER 71 OF 91 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [Azealaic acid for acne treatment: Pharmacology, in vitro and in vivo effects, clinical efficacy and tolerance].
AZELAINSÄURE FÜR DIE BEHANDLUNG DER AKNE:
PHARMAKOLOGIE, IN-VITRO- UND
IN-VIVO-EFFEKTE, SOWIE KLINISCHE ERGEBNISSE UND
TOLERANZ.
SO H+G Zeitschrift für Hautkrankheiten, (1992) 67/11 (975-987).
ISSN: 0301-0481 CODEN: ZHKRAJ

L4 ANSWER 72 OF 91 MEDLINE DUPLICATE 37
TI Growth characteristics and differentiation of basal cell carcinoma in vitro-immunohistochemical, gel electrophoretic, and ultrastructural analysis.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1992 Oct) 99 (4)
474-81.

Journal code: 0426720. ISSN: 0022-202X.

L4 ANSWER 73 OF 91 MEDLINE DUPLICATE 38
TI [Linear hyperpigmentation caused by bleomycin].
Flagellartige Hyperpigmentierung durch Bleomycin.
SO HAUTARZT, (1992 Jun) 43 (6) 376-9.
Journal code: 0372755. ISSN: 0017-8470.

L4 ANSWER 74 OF 91 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Recombinant tumour necrosis factor-alpha inhibits the proliferation of transformed human keratinocytes in vitro.
SO Skin Cancer, (1991) 6/3 (113-120).
ISSN: 0871-2549 CODEN: SKCAEC

L4 ANSWER 75 OF 91 MEDLINE DUPLICATE 39
TI Culture of human sebocytes and markers of sebocytic differentiation in vitro.
SO SKIN PHARMACOLOGY, (1991) 4 (2) 74-83.
Journal code: 8810069. ISSN: 1011-0283.

L4 ANSWER 76 OF 91 MEDLINE DUPLICATE 40
TI [Preliminary findings on lectin binding in human follicular epithelium].
Vorläufige Befunde zur Bindung von Lektinen im humanen folliculären Epithelium.
SO ZEITSCHRIFT FÜR HAUTKRANKHEITEN, (1990 Dec) 65 (12) 1123-7.
Journal code: 0367576. ISSN: 0301-0481.

L4 ANSWER 77 OF 91 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI Effects of rIFN alpha, beta, and gamma on the morphology, proliferation, and cell surface antigen expression of human dermal microvascular endothelial cells in vitro.
SO Journal of Investigative Dermatology, (1990) 95/6 (683-699).
ISSN: 0022-202X CODEN: JIDAE

L4 ANSWER 78 OF 91 MEDLINE DUPLICATE 41
TI Initial hyperproliferation and incomplete terminal differentiation of cultured human keratinocytes from lesional and uninvolved psoriatic skin.
SO ACTA DERMATO-VENEREOLOGICA, (1990) 70 (4) 295-9.
Journal code: 0370310. ISSN: 0001-5555.

L4 ANSWER 79 OF 91 MEDLINE DUPLICATE 42
TI Tumor necrosis factor-alpha inhibits cell proliferation and induces class II antigens and cell adhesion molecules in cultured normal human keratinocytes in vitro.
SO ARCHIVES OF DERMATOLOGICAL RESEARCH, (1990) 282 (4) 238-45.
Journal code: 8000462. ISSN: 0340-3696.

L4 ANSWER 80 OF 91 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI EFFECTS OF RECOMBINANT HUMAN TUMOR NECROSIS FACTOR-ALPHA ON NORMAL AND TRANSFORMED HUMAN KERATINOCTYES IN-VITRO.
SO JOINT MEETING OF THE SOCIETY FOR INVESTIGATIVE DERMATOLOGY, EUROPEAN SOCIETY FOR DERMATOLOGIC RESEARCH, AND JAPANESE SOCIETY FOR INVESTIGATIVE DERMATOLOGY, WASHINGTON, D.C., USA, APRIL 26-30, 1989. CLIN RES. (1989) 37 (2), 690A.
CODEN: CLREAS. ISSN: 0009-9279.

L4 ANSWER 81 OF 91 MEDLINE DUPLICATE 43
TI A rapid fluorometric assay for the determination of keratinocyte proliferation in vitro.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1989 Oct) 93 (4) 532-4.
Journal code: 0426720. ISSN: 0022-202X.

L4 ANSWER 82 OF 91 MEDLINE DUPLICATE 44
TI Isolation of human sebaceous glands and cultivation of sebaceous gland-derived cells as an in vitro model.
SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1989 Sep) 93 (3) 315-21.
Journal code: 0426720. ISSN: 0022-202X.

L4 ANSWER 83 OF 91 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.
TI [Autologous keratinocyte cultures as skin replacement for chronic venous ulcers].
AUTOLOGE KERATINOZYTENKULTUREN ALS HAUTERSATZ BEI LANGJÄHRIG BESTEHENDEN ULCERA CRURIS VENOSA.
SO Aktuelle Dermatologie, (1989) 15/4 (91-95).
ISSN: 0340-2541 CODEN: AKDEDY

L4 ANSWER 84 OF 91 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.
TI EFFECTS OF ETRETINATE AND AROTINOIDES ON THE KERATIN SYNTHESIS OF HUMAN KERATINOCTYES CULTURED AT THE LIQUID-AIR INTERFACE.
SO REICHERT, U. AND B. SHROUT (ED.). PHARMACOLOGY AND THE SKIN, VOL. 3.

PHARMACOLOGY OF RETINOIDS IN THE SKIN; 8TH CIRD (CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES) SYMPOSIUM ON ADVANCES IN SKIN PHARMACOLOGY, CANNES, FRANCE, SEPTEMBER 1-3, 1988. X+282P. S. KARGER AG: BASEL, SWITZERLAND; NEW YORK, NEW YORK, USA. ILLUS. (1989) 0 (0), 86-87.

CODEN: PHSKY. ISBN: 3-8055-4909-1.

L4 ANSWER 85 OF 91 MEDLINE DUPLICATE 45

TI Effects of azelaic acid on proliferation and ultrastructure of mouse keratinocytes in vitro.

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1989 Jul) 93 (1) 70-4.

Journal code: 0426720. ISSN: 0022-202X.

L4 ANSWER 86 OF 91 MEDLINE

TI Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin. An in vivo and in vitro study.

SO ACTA DERMATO-VENEREOLOGICA. SUPPLEMENTUM, (1989) 143 (20-30).

Journal code: 0370311. ISSN: 0365-8341.

L4 ANSWER 87 OF 91 EMBASE COPYRIGHT 2003 ELSEVIER SCI. B.V.

TI Effects of azelaic acid on sebaceous gland, sebum excretion rate and keratinization pattern in human skin. An in vivo and in vitro study.

SO Acta Dermato-Venereologica, Supplement, (1989) 69/143 (20-30).

ISSN: 0365-8431 CODEN: AVSUAR

L4 ANSWER 88 OF 91 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI NEW POTENT AROTINOID DERIVATIVES MODIFY GROWTH AND DIFFERENTIATION OF

CULTURED MURINE AND HUMAN KERATINOCYTES.

SO REICHERT, U. AND B. SHROUT (ED.). PHARMACOLOGY AND THE SKIN, VOL. 3.

PHARMACOLOGY OF RETINOIDS IN THE SKIN; 8TH CIRD (CENTRE INTERNATIONAL DE RECHERCHES DERMATOLOGIQUES) SYMPOSIUM ON ADVANCES IN SKIN PHARMACOLOGY, CANNES, FRANCE, SEPTEMBER 1-3, 1988. X+282P. S. KARGER AG: BASEL, SWITZERLAND; NEW YORK, NEW YORK, USA. ILLUS. (1989) 0 (0), 15-19.

CODEN: PHSKY. ISBN: 3-8055-4909-1.

L4 ANSWER 89 OF 91 MEDLINE DUPLICATE 46

TI Growth of human hair follicle keratinocytes in vitro.

Ultrastructural features of a new model.

SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, (1987 Nov) 17 (5 Pt 1) 779-86.

Journal code: 7907132. ISSN: 0190-9622.

L4 ANSWER 90 OF 91 MEDLINE DUPLICATE 47

TI Retinoids and keratinocyte differentiation in vitro.

SO DERMATOLOGICA, (1987) 175 Suppl 1 45-55.

Journal code: 0211607. ISSN: 0011-9075.

L4 ANSWER 91 OF 91 MEDLINE DUPLICATE 48

TI [Dicarboxylic acids inhibit the growth of keratinocytes in vitro].

Dicarbonsäuren hemmen das Wachstum von Keratinozyten in vitro.

SO HAUTARZT, (1986 Nov) 37 (11) 625-7.

Journal code: 0372755. ISSN: 0017-8470.

=> d his

(FILE 'HOME' ENTERED AT 14:56:08 ON 29 JUN 2003)

FILE 'MEDLINE, BIOSIS, CAPLUS, CANCERLIT, EMBASE' ENTERED AT 14:56:32 ON 29 JUN 2003

L1 21 S YANO-K//AU AND (VEGF OR KERATINOCYTE OR HAIR)

L2 12 DUP REM L1 (9 DUPLICATES REMOVED)

L3 233 S DETMAR-M//AU AND (VEGF OR KERATINO? OR HAIR)

L4 91 DUP REM L3 (142 DUPLICATES REMOVED)

=> s detmar-m//au and keratino? and (vegf or hair)

L5 66 DETMAR-M//AU AND KERATINO? AND (VEGF OR HAIR)

=> dup rem 15

PROCESSING COMPLETED FOR L5

L6 23 DUP REM L5 (43 DUPLICATES REMOVED)

=> d 1-23 ti so

L6 ANSWER 1 OF 23 MEDLINE DUPLICATE 1

TI A critical role of placental growth factor in the induction of inflammation and edema formation.

SO BLOOD, (2003 Jan 15) 101 (2) 560-7.

Journal code: 7603509. ISSN: 0006-4971.

L6 ANSWER 2 OF 23 MEDLINE

TI Transgenic delivery of VEGF to mouse skin leads to an inflammatory condition resembling human psoriasis.

SO BLOOD, (2003 Jul 1) 102 (1) 161-8.

Journal code: 7603509. ISSN: 0006-4971.

L6 ANSWER 3 OF 23 MEDLINE DUPLICATE 2

TI Thrombospondin-1 plays a critical role in the induction of hair follicle involution and vascular regression during the catagen phase.

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (2003 Jan) 120 (1) 14-9.

Journal code: 0426720. ISSN: 0022-202X.

L6 ANSWER 4 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI Suppression of multistage skin carcinogenesis in mice deficient for placental growth factor.

SO Journal of Investigative Dermatology, (July, 2002) Vol. 119, No. 1, pp. 224. http://www.jidonline.org. print.

Meeting Info.: 63rd Annual Meeting of the Society for Investigative Dermatology Los Angeles, California, USA May 15-18, 2002

ISSN: 0022-202X.

L6 ANSWER 5 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI A critical role of placental growth factor in the induction and maintenance of cutaneous inflammation and edema formation.

SO Journal of Investigative Dermatology, (July, 2002) Vol. 119, No. 1, pp. 211. http://www.jidonline.org. print.

Meeting Info.: 63rd Annual Meeting of the Society for Investigative Dermatology Los Angeles, California, USA May 15-18, 2002

ISSN: 0022-202X.

L6 ANSWER 6 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI The endogenous angiogenesis inhibitor thrombospondin-1 plays a critical role in the induction of hair follicle involution and vascular regression during catagen.

SO Journal of Investigative Dermatology, (July, 2002) Vol. 119, No. 1, pp. 208. http://www.jidonline.org. print.

Meeting Info.: 63rd Annual Meeting of the Society for Investigative Dermatology Los Angeles, California, USA May 15-18, 2002

ISSN: 0022-202X.

L6 ANSWER 7 OF 23 CAPLUS COPYRIGHT 2003 ACS

TI Methods of modulating hair growth

SO PCT Int. Appl., 66 pp.

CODEN: PIXXD2

L6 ANSWER 8 OF 23 MEDLINE DUPLICATE 3

TI Control of hair growth and follicle size by VEGF -mediated angiogenesis.

SO JOURNAL OF CLINICAL INVESTIGATION, (2001 Feb) 107 (4) 409-17.

Journal code: 7802877. ISSN: 0021-9738.

L6 ANSWER 9 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI Inverse regulation of the angiogenesis factor VEGF and the angiogenesis inhibitors thrombospondin-1 and TSP-2 in human epidermal keratinocytes.

SO Journal of Investigative Dermatology, (August, 2001) Vol. 117, No. 2, pp. 391. print.

Meeting Info.: 62nd Annual Meeting of the Society for Investigative Dermatology Washington, DC, USA May 09-12, 2001

ISSN: 0022-202X.

L6 ANSWER 10 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI Murine hair follicle growth is angiogenesis-dependent.

SO Journal of Investigative Dermatology, (April, 2000) Vol. 114, No. 4, pp. 755.

Meeting Info.: 61st Annual Meeting of the Society for Investigative Dermatology Chicago, Illinois, USA May 10-14, 2000

ISSN: 0022-202X.

L6 ANSWER 11 OF 23 MEDLINE DUPLICATE 4

TI In vivo detection of human vascular endothelial growth factor promoter activity in transgenic mouse skin.

SO AMERICAN JOURNAL OF PATHOLOGY, (2000 Jul) 157 (1) 103-10.

Journal code: 0370502. ISSN: 0002-9440.

L6 ANSWER 12 OF 23 MEDLINE DUPLICATE 5

TI The role of VEGF and thrombospondins in skin angiogenesis.

SO JOURNAL OF DERMATOLOGICAL SCIENCE, (2000 Dec) 24 Suppl 1 S78-84. Ref: 30

Journal code: 9011485. ISSN: 0923-1811.

L6 ANSWER 13 OF 23 MEDLINE DUPLICATE 6

TI Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice.

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1998 Jul) 111 (1) 1-6.
Journal code: 0426720. ISSN: 0022-202X.

L6 ANSWER 14 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI Antisense oligonucleotides inhibit vascular endothelial growth factor (VEGF) expression in normal human epidermal keratinocytes

SO Journal of Investigative Dermatology, (1997) Vol. 108, No. 4, pp. 678.
Meeting Info.: Annual Meeting of the Society for Investigative Dermatology Washington, D.C., USA April 23-27, 1997
ISSN: 0022-202X.

L6 ANSWER 15 OF 23 MEDLINE DUPLICATE 7

TI Antisense oligonucleotides inhibit vascular endothelial growth factor/vascular permeability factor expression in normal human epidermal keratinocytes.

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1997 Apr) 108 (4) 523-6.

Journal code: 0426720. ISSN: 0022-202X.

L6 ANSWER 16 OF 23 MEDLINE DUPLICATE 8

TI Hypoxia regulates the expression of vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) and its receptors in human skin.

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1997 Mar) 108 (3) 263-8.

Journal code: 0426720. ISSN: 0022-202X.

L6 ANSWER 17 OF 23 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC.

TI Placenta growth factor, a new member of the VPF/VEGF family, is expressed by epidermal keratinocytes and dermal microvascular endothelial cells in vitro and in vivo.

SO Journal of Investigative Dermatology, (1996) Vol. 106, No. 4, pp. 835.
Meeting Info.: Annual Meeting of the Society for Investigative Dermatology Washington, D.C., USA May 1-5, 1996
ISSN: 0022-202X.

L6 ANSWER 18 OF 23 MEDLINE DUPLICATE 9

TI Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis.

SO AMERICAN JOURNAL OF PATHOLOGY, (1995 May) 146 (5) 1029-39.

Ref. 121

Journal code: 0370502. ISSN: 0002-9440.

L6 ANSWER 19 OF 23 MEDLINE DUPLICATE 10

TI Increased expression of vascular permeability factor (vascular endothelial growth factor) in bullous pemphigoid, dermatitis herpetiformis, and erythema multiforme.

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1995 May) 104 (5) 744-9.

Journal code: 0426720. ISSN: 0022-202X.

L6 ANSWER 20 OF 23 MEDLINE DUPLICATE 11

TI Keratinocyte-derived vascular permeability factor (vascular endothelial growth factor) is a potent mitogen for dermal microvascular endothelial cells.

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1995 Jul) 105 (1) 44-50.

Journal code: 0426720. ISSN: 0022-202X.

L6 ANSWER 21 OF 23 MEDLINE DUPLICATE 12

TI Vellus hair follicle-derived keratinocyte culture: a new experimental model in human hair research.

SO SKIN PHARMACOLOGY, (1994) 7 (1-2) 27-32.

Journal code: 8810069. ISSN: 1011-0283.

L6 ANSWER 22 OF 23 MEDLINE DUPLICATE 13

TI Culture of hair matrix and follicular keratinocytes.

SO JOURNAL OF INVESTIGATIVE DERMATOLOGY, (1993 Jul) 101 (1 Suppl) 130S-134S.

Ref. 56

Journal code: 0426720. ISSN: 0022-202X.

L6 ANSWER 23 OF 23 MEDLINE DUPLICATE 14

TI Growth of human hair follicle keratinocytes in vitro.

Ultrastructural features of a new model.

SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, (1987 Nov) 17 (5 Pt 1) 779-86.

Journal code: 7907132. ISSN: 0190-9622.

=> d 23 ab

L6 ANSWER 23 OF 23 MEDLINE DUPLICATE 14

AB A simple experimental technique was developed to provide an *in vitro* model for the study of human follicular keratinocytes. Anagen-phase human hairs were plucked from the scalp of healthy individuals; the follicles were separated, plated on coverslips coated with collagen G, and cultivated in McCoy 5A Medium in a CO₂-incubator at 37 degrees C.

Light and electron microscopy after 1, 2, 3, and 6 weeks showed selective and progressive cell growth with keratinocyte differentiation, producing multilayered cultures of cells joined with fully developed desmosomes. Three distinct patterns of differentiation, leading to the formation of an incomplete horny layer, were seen. The particular arrangement of tonofilaments, the considerable amounts of cytoplasmic glycogen, and the absence of malpighian differentiation were ultrastructural indicators of the follicular origin of the cultured cell population, which most likely grew from the outer root sheath of the hair. This technique may provide a promising model on which to base further studies of hair biologic processes and hair growth.

=> d 18 ab

L6 ANSWER 18 OF 23 MEDLINE DUPLICATE 9

AB VPF/VEGF is a multifunctional cytokine that contributes to angiogenesis by both direct and indirect mechanisms. On the one hand, VPF/VEGF stimulates the ECs lining nearby microvessels to proliferate, to migrate, and to alter their pattern of gene expression. On the other hand, VPF/VEGF renders these same microvascular ECs hyperpermeable so that they spill plasma proteins into the extravascular space, leading to the clotting of extravasated fibrinogen with deposition of a fibrin gel. Extravascular fibrin serves as a provisional matrix that favors and supports the ingrowth of new blood vessels and other mesenchymal cells that generate mature, vascularized stroma. These same principles apply in tumors, in several examples of non-neoplastic pathology, and in physiological processes that involve angiogenesis and new stroma generation. In all of these examples, microvascular hyperpermeability and the introduction of a provisional, plasma-derived matrix precede and accompany the onset of EC division and new blood vessel formation. It would seem, therefore, that tumors have "borrowed" fundamental mechanisms that developed in multicellular organisms for purposes of tissue defense, renewal, and repair. VPF/VEGF, therefore has taught us something new about angiogenesis; namely, that vascular hyperpermeability and consequent plasma protein extravasation are important, perhaps essential, elements in its generation. However, this finding raises a paradox. While VPF/VEGF induces vascular hyperpermeability, other potent angiogenic factors apparently do not, at least in subtoxic concentrations that are more than sufficient to induce angiogenesis. Nonetheless, wherever angiogenesis has been studied, the newly generated vessels have been found to be hyperpermeable. How, therefore, do angiogenic factors other than VPF/VEGF lead to the formation of new and leaky blood vessels? We do not as yet have a complete answer to this question. One possibility is that at least some angiogenic factors mediate their effect by inducing or stimulating the expression of VPF/VEGF. In fact, there is already one clear example of this. TGF-alpha is a potent angiogenic factor but does not itself increase microvascular permeability. However, TGF-alpha strikingly upregulates VPF/VEGF expression in cultured keratinocytes and is thought to be responsible, at least in part, for the overexpression of VPF/VEGF in psoriasis. Moreover, overexpression of TGF-alpha, along with that of the EGF receptor with which it interacts, is characteristic of many malignant tumors, raising the possibility that TGF-alpha acts to stimulate VPF/VEGF expression in other types of epithelial cells and in this manner induces angiogenesis. (ABSTRACT TRUNCATED AT 400 WORDS)

=> d 15 ab

L6 ANSWER 15 OF 23 MEDLINE DUPLICATE 7

AB In psoriatic lesions, epidermal keratinocytes overexpress vascular endothelial growth factor/vascular permeability factor (VEGF/VPF) and transforming growth factor alpha (TGF-alpha). TGF-alpha has been shown to induce VEGF/VPF in normal human epidermal keratinocytes *in vitro*. By using a 19-mer antisense phosphorothioate oligodeoxynucleotide (PS-ODN) complementary to bases 6-

24 relative to the translational start site of the VEGF/VPF mRNA, the control sense and mismatched PS-ODNs, we examined modulation of VEGF/VPF induction by TGF-alpha *in vitro*. Normal human epidermal keratinocytes were treated with PS-ODNs and Lipofectin for 8 h prior to the addition of TGF-alpha. Inhibition was assayed at the level of secreted protein by capture ELISA and mRNA expression was assayed by Northern blot analysis. The anti-sense PS-ODN was capable of inhibiting VEGF/VPF RNA and protein to near-basal levels. This inhibition was concentration dependent. No effect was observed with the sense or mismatch control PS-ODNs. These studies suggest that antisense oligonucleotide technology may be a potential therapy for the inhibition of angiogenesis associated with certain skin disorders such as psoriasis.

=> d 16 ab

L6 ANSWER 16 OF 23 MEDLINE DUPLICATE 8

AB Tissue hypoxia is a characteristic feature of malignant tumors and healing wounds, conditions that are associated with angiogenesis and with increased expression of vascular permeability factor (VPF; also called vascular endothelial growth factor, VEGF), a selective endothelial cell mitogen inducing microvascular hyperpermeability *in vivo*. We investigated the regulation of VPF/VEGF and its receptors by

tissue hypoxia in normal human skin explants and in cultured skin cells in vitro. VPF/VEGF mRNA expression was dramatically upregulated in epidermal keratinocytes, dermal fibroblasts, and dermal microvessels after 24 h of skin organ culture. Hypoxia also enhanced the expression of VPF/VEGF in cultured epidermal keratinocytes and dermal microvascular endothelial cells (predominantly VPF/VEGF121 and VPF/VEGF165) and in dermal fibroblasts (additional upregulation of VPF/VEGF189). The expression of the VPF/VEGF receptor Flt-1 was selectively induced on dermal microvessels in skin explant cultures and in dermal endothelial cell monolayer cultures under hypoxic conditions. In contrast, the KDR receptor was downregulated by hypoxia. These results suggest that hypoxia likely regulates cutaneous angiogenesis and microvascular permeability by two distinct mechanisms: (i) Induction of VPF/VEGF in epithelial and mesenchymal cells, including endothelial cells. (ii) Differential modulation of VPF/VEGF receptor expression by microvascular endothelial cells. These mechanisms may be of importance in the pathogenesis of healing wounds and some malignant tumors that are commonly characterized by hypoxia and overexpression of VPF/VEGF.

=> d 8 ab

L6 ANSWER 8 OF 23 MEDLINE DUPLICATE 3
 AB The murine hair follicle undergoes pronounced cyclic expansion and regression, leading to rapidly changing demands for its vascular support. Our study aimed to quantify the cyclic changes of perifollicular vascularization and to characterize the biological role of VEGF for hair growth, angiogenesis, and follicle cycling. We found a significant increase in perifollicular vascularization during the growth phase (anagen) of the hair cycle, followed by regression of angiogenic blood vessels during the involution (catagen) and the resting (telogen) phase. Perifollicular angiogenesis was temporally and spatially correlated with upregulation of VEGF mRNA expression by follicular keratinocytes of the outer root sheath, but not by dermal papilla cells. Transgenic overexpression of VEGF in outer root sheath keratinocytes of hair follicles strongly induced perifollicular vascularization, resulting in accelerated hair regrowth after depilation and in increased size of hair follicles and hair shafts. Conversely, systemic treatment with a neutralizing anti-VEGF antibody led to hair growth retardation and reduced hair follicle size. No effects of VEGF treatment or VEGF blockade were observed in mouse vibrissa organ cultures, which lack a functional vascular system. These results identify VEGF as a major mediator of hair follicle growth and cycling and provide the first direct evidence that improved follicle vascularization promotes hair growth and increases hair follicle and hair size.

=> d 8 au ti so

L6 ANSWER 8 OF 23 MEDLINE DUPLICATE 3
 AU Yano K; Brown L F; Detmar M
 TI Control of hair growth and follicle size by VEGF -mediated angiogenesis.
 SO JOURNAL OF CLINICAL INVESTIGATION, (2001 Feb) 107 (4) 409-17.
 Journal code: 7802877. ISSN: 0021-9738.

=> s VEGF and hair
 L7 121 VEGF AND HAIR

=> dup rem l7
 PROCESSING COMPLETED FOR L7
 L8 49 DUP REM L7 (72 DUPLICATES REMOVED)

=> d 30-39 ti so

L8 ANSWER 30 OF 49 CAPLUS COPYRIGHT 2003 ACS
 TI Infrared thermography for measuring real-time thermogenesis in organisms and cells
 SO PCT Int. Appl., 93 pp.
 CODEN: PIXXD2

L8 ANSWER 31 OF 49 CAPLUS COPYRIGHT 2003 ACS
 TI Methods and compositions for inhibiting angiogenesis using SLED
 SO PCT Int. Appl., 30 pp.
 CODEN: PIXXD2

L8 ANSWER 32 OF 49 MEDLINE DUPLICATE 13
 TI Anti-androgens and estrogens: modulators of VEGF expression in cultured hair dermal papilla cells.
 SO EXPERIMENTAL DERMATOLOGY, (1999 Aug) 8 (4) 336-8.
 Journal code: 9301549. ISSN: 0906-6705.

L8 ANSWER 33 OF 49 MEDLINE DUPLICATE 14
 TI In vitro main pathways of steroid action in cultured hair follicle cells: vascular approach.
 SO JOURNAL OF INVESTIGATIVE DERMATOLOGY. SYMPOSIUM PROCEEDINGS, (1999 Dec) 4 (3) 290-5.

Journal code: 9609059. ISSN: 1087-0024.

L8 ANSWER 34 OF 49 MEDLINE DUPLICATE 15
 TI Controlled delivery of vascular endothelial growth factor promotes neovascularization and maintains limb function in a rabbit model of ischemia.
 SO JOURNAL OF VASCULAR SURGERY, (1998 May) 27 (5) 886-94; discussion 895.
 Journal code: 8407742. ISSN: 0741-5214.

L8 ANSWER 35 OF 49 MEDLINE DUPLICATE 16
 TI Expression of vascular endothelial growth factor (VEGF) in various compartments of the human hair follicle.
 SO ARCHIVES OF DERMATOLOGICAL RESEARCH, (1998 Dec) 290 (12) 661-8.
 Journal code: 8000462. ISSN: 0340-3696.

L8 ANSWER 36 OF 49 MEDLINE DUPLICATE 17
 TI Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells.
 SO BRITISH JOURNAL OF DERMATOLOGY, (1998 Mar) 138 (3) 407-11.
 Journal code: 0004041. ISSN: 0007-0963.

L8 ANSWER 37 OF 49 MEDLINE DUPLICATE 18
 TI [Pilar growth: VEGF and fibroblasts of the follicular papilla].
 Croissance pilaire: VEGF et fibroblastes de la papille folliculaire.
 SO ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, (1998 Nov) 125 Suppl 2 S9-11.
 Journal code: 7702013. ISSN: 0151-9638.

L8 ANSWER 38 OF 49 BIOSIS COPYRIGHT 2003 BIOLOGICAL ABSTRACTS INC. DUPLICATE 19
 TI Hair growth: VEGF and the hair follicle fibroblasts.
 SO Annales de Dermatologie et de Venereologie, (Nov., 1998) Vol. 125, No. SUPPL. 2, pp. 2S9-2S11.
 ISSN: 0151-9638.

L8 ANSWER 39 OF 49 MEDLINE DUPLICATE 20
 TI Angiogenesis: a dynamic balance of stimulators and inhibitors.
 SO THROMBOSIS AND HAEMOSTASIS, (1997 Jul) 78 (1) 672-7. Ref: 60
 Journal code: 7608063. ISSN: 0340-6245.

=> d 36 ab

L8 ANSWER 36 OF 49 MEDLINE DUPLICATE 17
 AB The hair follicle dermal papilla which controls hair growth, is characterized in the anagen phase by a highly developed vascular network. We have demonstrated in a previous study that the expression of an angiogenic growth factor called vascular endothelial growth factor (VEGF) mRNA varied during the hair cycle. VEGF mRNA is strongly expressed in dermal papilla cells (DPC) in the anagen phase, but during the catagen and telogen phases, VEGF mRNA is less strongly expressed. This involvement of VEGF during the hair cycle allowed us to determine whether VEGF mRNA expression by DPC was regulated by minoxidil. In addition, the effect of minoxidil on VEGF protein synthesis in both cell extracts and DPC-conditioned medium, was investigated immunoenzymatically. Both VEGF mRNA and protein were significantly elevated in treated DPC compared with controls. DPC incubated with increasing minoxidil concentrations (0.2, 2, 6, 12 and 24 μ mol/L) induced a dose-dependent expression of VEGF mRNA. Quantification of transcripts showed that DPC stimulated with 24 μ mol/L minoxidil express six times more VEGF mRNA than controls. Similarly, VEGF protein production increases in cell extracts and conditioned media following minoxidil stimulation. These studies strongly support the likely involvement of minoxidil in the development of dermal papilla vascularization via a stimulation of VEGF expression, and support the hypothesis that minoxidil has a physiological role in maintaining a good vascularization of hair follicles in androgenetic alopecia.

=> d 36 au ti so

L8 ANSWER 36 OF 49 MEDLINE DUPLICATE 17
 AU Lachgar S; Charveron M; Gall Y; Bonafe J L
 TI Minoxidil upregulates the expression of vascular endothelial growth factor in human hair dermal papilla cells.
 SO BRITISH JOURNAL OF DERMATOLOGY, (1998 Mar) 138 (3) 407-11.
 Journal code: 0004041. ISSN: 0007-0963.

=>
 Connection closed by remote host